Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tina Visboll"'
Autor:
Caroline Miranda, Lisa Mellander, Filip K. Knop, Patrick E. MacDonald, Thomas Hill, Victoria Salem, Lina Abdul-Kadir, Patrik Rorsman, Ingrid Wernstedt Asterholm, Linford Jb Briant, Joseph C. Madara, Yanling Wu, Kinga Suba, Bradford B. Lowell, Anna Benrick, Tim James, Angela Kim, Jakob G. Knudsen, Tina Visboll, Mikkel Christensen, Haopeng Lin, Joely A. Kellard, Tore Magnussen, Aliya F. Spigelman
Publikováno v:
Kim, A, Knudsen, J G, Madara, J C, Benrick, A, Hill, T G, Kadir, L A, Kellard, J A, Mellander, L, Miranda, C, Lin, H, James, T, Suba, K, Spigelman, A F, Wu, Y, Macdonald, P E, Asterholm, I W, Magnussen, T, Christensen, M, Vilsbøll, T, Salem, V, Knop, F K, Rorsman, P, Lowell, B B & Briant, L J B 2021, ' Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes ', eLife, vol. 10, e72919 . https://doi.org/10.7554/eLife.72919
eLife
eLife, Vol 10 (2021)
eLife
eLife, Vol 10 (2021)
Insulin-induced hypoglycemia is a major barrier to the treatment of type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon – the body’s principal blood glucose-elevating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0ca0d2bfb4fa800a3a896ff4db17a3e
https://curis.ku.dk/portal/da/publications/argininevasopressin-mediates-counterregulatory-glucagon-release-and-is-diminished-in-type-1-diabetes(c2f8cf88-f4b7-446a-be02-47d73f846764).html
https://curis.ku.dk/portal/da/publications/argininevasopressin-mediates-counterregulatory-glucagon-release-and-is-diminished-in-type-1-diabetes(c2f8cf88-f4b7-446a-be02-47d73f846764).html
Autor:
Bradford B. Lowell, Tina Visboll, Timothy Y. James, Haopeng Lin, Thomas Hill, Jakob G. Knudsen, Kinga Suba, Victoria Salem, Lina Abdul Kadir, Ingrid Wernstedt Asterholm, Lisa Mellander, Patrick E. MacDonald, Filip K. Knop, Tore Magnussen, Linford J.B. Briant, Caroline Miranda, Aliya F. Spigelman, Anna Benrick, Joseph C. Madara, Patrik Rorsman, Yanling Wu, Mikkel Christensen, Angela Kim, Joely A. Kellard
Insulin-induced hypoglycemia is a major barrier to the treatment of type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon – the body’s principal blood glucose-elevating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44a862ee1eb78e682f6f9ef9c4ffbca3
https://doi.org/10.1101/2020.01.30.927426
https://doi.org/10.1101/2020.01.30.927426